Back

Correction to: XANTUS: a real-world, prospective, observational study of patients treated with rivaroxaban for stroke prevention in atrial fibrillation

European Heart Journal

17 April 2024
Organised by: Logo
Read full article
ESC Journals
You may be interested in
thumbnail
Congress Presentation
Anticoagulation after embolic stroke of undetermined source - therapeutic dilemmas.
31 August 2025
thumbnail
Congress Presentation
Comparative effectiveness and safety of apixaban and low-molecular weight heparin among patients with venous thromboembolism and active cancer in an extended treatment setting
28 August 2023
thumbnail
Congress Presentation
Adherence and treatment satisfaction among atrial fibrillation patients treated with VKAs versus NOACs: real-world data from a single-center cohort
12 April 2026
thumbnail
Congress Presentation
Comparison of baseline characteristics and outcomes of on-label full dose (20mg) and off-label reduced dose (15mg) rivaroxaban in patients with atrial fibrillation in Asian elderly patients
25 August 2023

ESC 365 is supported by

novartis Explore sponsored resources
novo-nordisk Explore sponsored resources